LadRx (OTCMKTS:CYTR) & MiNK Therapeutics (NASDAQ:INKT) Critical Contrast
LadRx (OTCMKTS:CYTR) & MiNK Therapeutics (NASDAQ:INKT) Critical Contrast
LadRx (OTCMKTS:CYTR – Get Rating) and MiNK Therapeutics (NASDAQ:INKT – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.
LADRX (OTCMKTS: CYTR — 獲得評級) 和貂皮治療 (NASDAQ: 墨水 — 獲取評級) 都是小型股醫療公司, 但哪個是更好的業務?我們將根據兩家企業的風險，估值，股息，機構所有權，分析師建議，盈利和盈利能力對比這兩家企業。
Earnings & Valuation
盈利及估值
This table compares LadRx and MiNK Therapeutics' gross revenue, earnings per share and valuation.
此表格比較了 LaDrX 和貂皮治療的總收入，每股盈利和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| LadRx | N/A | N/A | -$6.70 million | ($0.15) | N/A |
| MiNK Therapeutics | N/A | N/A | -$30.21 million | ($0.78) | -2.71 |
| 總收入 | 價格/銷售比率 | 淨收入 | 每股盈利 | 市盈比率 | |
| LADRX | N/A | N/A | -670 萬美元 | (0.15 美元) | N/A |
| 貂皮治療 | N/A | N/A | -三千一百二十一萬美元 | (0.78 美元) | -2.71 |
MiNK Therapeutics is trading at a lower price-to-earnings ratio than LadRx, indicating that it is currently the more affordable of the two stocks.
MINK 治療學的交易價格與收益比低於 LaDrX，這表明它目前在兩隻股票中價格更便宜。
Profitability
盈利
This table compares LadRx and MiNK Therapeutics' net margins, return on equity and return on assets.
此表格比較了 LaDrX 和明克治療的淨利潤率、權益回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| LadRx | N/A | -67.61% | -45.39% |
| MiNK Therapeutics | N/A | -168.94% | -78.30% |
| 淨利潤 | 權益回報率 | 資產回報率 | |
| LADRX | N/A | -67.61% | -45.39% |
| 貂皮治療 | N/A | -168.94% | -78.30% |
Risk & Volatility
風險及波動性
LadRx has a beta of 1.96, suggesting that its stock price is 96% more volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of -0.66, suggesting that its stock price is 166% less volatile than the S&P 500.
LADRX 的測試值為 1.96，表明其股票價格的波動性比標普 500 高出 96％。相比之下，貂治療的測試值為 -0.66，這表明其股票價格的波動性比標普 500 低 166%。
Analyst Recommendations
分析師推薦
This is a breakdown of recent ratings and target prices for LadRx and MiNK Therapeutics, as provided by MarketBeat.
這是由 MarketBeat 提供的 LaDrX 和貂皮治療的近期評分和目標價格的細分。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| LadRx | 0 | 0 | 0 | 0 | N/A |
| MiNK Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
| 銷售評級 | 保留評分 | 購買評級 | 強大的買入評級 | 評級分數 | |
| LADRX | 0 | 0 | 0 | 0 | N/A |
| 貂皮治療 | 0 | 0 | 1 | 0 | 3.00 |
MiNK Therapeutics has a consensus target price of $7.00, indicating a potential upside of 231.75%.
貂治療學的共識目標價為 7.00 美元，表明潛在的上行空間為 231.75％。
Institutional & Insider Ownership
機構和內幕所有權
0.1% of LadRx shares are held by institutional investors. Comparatively, 1.4% of MiNK Therapeutics shares are held by institutional investors. 12.8% of LadRx shares are held by company insiders. Comparatively, 13.2% of MiNK Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
0.1％ 的股票由機構投資者持有。相比之下，1.4% 的 MINK 治療股份由機構投資者持有。12.8% 的 LADRX 股份由公司內部人士持有。相比之下，13.2％ 的 MinK 治療學股份由公司內部人士持有。強大的機構所有權表明，大型資金經理，對沖基金和捐贈基金認為一家公司有望實現長期增長。
Summary
摘要
LadRx beats MiNK Therapeutics on 6 of the 9 factors compared between the two stocks.
與兩隻股票之間的 9 個因素中的 6 個因素相比，LaDrX 擊敗了貂皮治療。
About LadRx
關於我們
(Get Rating)
(取得評分)
LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.
LADRX Corporation 是一家生物製藥公司，致力於治療癌症患者的治療藥物的發現和開發。該公司的先進藥物共軛，阿多柔比星是在後期臨床試驗中是抗癌藥物多柔比星的一個版本。其臨床前治療包括鏈接器活性藥物釋放 7、8、9 和 10 針對癌症。該公司以前稱為 CyTRX 公司，並於 2022 年 9 月更名為 LADRX 公司。LADRX 公司成立於 1985 年，總部位於加利福尼亞州洛杉磯。
About MiNK Therapeutics
關於 MINK 治療
(Get Rating)
(取得評分)
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Mink Therapical, Inc. 是一家臨床階段生物製藥公司，致力於同種異體、現成、不變自然殺手 T (InkT) 細胞療法的發現、開發和商業化，以治療癌症和其他免疫介導的疾病。其候選產品是 AGENT-797，這是一種現成的，用於 InkT 細胞治療和治療各種骨髓瘤疾病的同種異體藥物，該疾病處於 1 期臨床試驗中。該公司以前被稱為 AgenTUS 治療有限公司 MINK 治療有限公司成立於 2017 年，總部設在紐約州紐約。貂治療有限公司作為 Agenus 公司的子公司運營。
Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.
接收有關 LaDrX 每日的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收對 LADRX 及相關公司的最新新聞和分析師評級的簡要每日摘要。